Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
The origin and impact of impaired ubiquitin signaling in the degeneration of neurons (Ubi-Wan)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Molecules of Life: B iological  Mechanisms , Structures  and Functions
Panel description: For all organisms : Molecular biology , biochemistry, structural biology, molecular biophysics , synthetic and chemical biology, drug design, innovative methods and modelling
Countries involved: Israel
Call: ERC ADVANCED GRANTS (ERC-2023-ADG, 2023)
Start date: 2024-11-01
End date: 2029-10-31
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Neurodegenerative diseases share similar hallmarks such as protein aggregation, suggesting that impaired protein degradation may be a common denominator. The major cellular pathways mediating protein degradation are the Ubiquitin-proteasome system (UPS) and autophagy, both regulated by ubiquitin signaling. However, aside from specific mutations in familial neurodegeneration cases, an early cause for failing ubiquitin-dependent proteolysis remains unclear. This proposal will test our unconventional hypothesis that dysregulated ubiquitin signaling is an early event in mechanisms of neurodegeneration, linking together numerous disease hallmarks. Towards this goal, we present groundbreaking findings that a mutated UPS protein resulting from a non-heritable transcription frameshift and present in the brains of neurodegenerative patients, particularly Alzheimer's disease (AD), is sufficient to trigger disease hallmarks in 3-D human neuronal cultures. This unique set-up replicates the main pathological hallmarks of AD without relying on any of the known genetic causes or risk factors. Utilizing this novel model, we have identified a previously unknown enzyme active site in a key neuroprotective protein, which now allows us to study the role of ubiquitin signaling in disease pathology. Specifically, this proposal seeks to understand both the source of disease-related ubiquitin signaling deterioration and its impact on neurons, by: 1) Studying the mechanisms that trigger disruption of ubiquitin signaling in neurons. 2) Understanding the consequences of altered ubiquitin signaling in human neuronal models of AD. 3) Searching for mechanisms of neuroprotection mediated by key enzymes of the UPS. The outcome will develop new models of neurodegeneration, improve methods to study ubiquitin signaling in neurons, and yield a mechanistic understanding of UPS components in neuronal health and disease. Furthermore, the results will pave the way for developing new treatment approaches.

Keywords: alzheimer s disease,proteostasis,proteasome,ubiquitin,autophagy,aging,proteolysis,deubiquitination,neurodegeneration,protein aggregates,stem cell models,3d neural models
GATE2BRAIN TOWARDS SME DESIGNATION AND PAEDIATRIC INVESTIGATIONAL PLAN (G2B-002)

Framework: Horizon Europe — Innovative Europe
Programme: European innovation ecosystems
Theme: Elevating the scalability potential of European business
Destination: Elevating the scalability potential of European business
Action type: Coordination and support actions
Countries involved: Spain
Call: Women TechEU (HORIZON-EIE-2022-SCALEUP-02, 2022)
Start date: 2023-08-01
End date: 2024-07-31
Duration (months): 12.0
Total project cost (EUR): 107142.86
EU funding (EUR): 75000.0
Participants: 1
Project status: CLOSED

Gate2Brain (G2B) is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier (BBB). Using this radically innovative peptide-based patented technology platform, G2B has developed a novel therapy, G2B-002, for pediatric brain tumors such as Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma, currently without a cure or poor prognosis. Small and medium-size enterprises (SMEs) represent 99% of all business in the EU. G2B will apply to obtain SME designation to have access to finance and EU support programs which include research, competitiveness, and innovation funding. Another potential benefit that G2B could obtain is the fewer requirements or reduced fees for EU administrative compliance. G2B is mainly focused on pediatric brain cancer, a rare but mostly lethal Central Nervous System disease. After obtaining SME designation, G2B will develop the Paediatric Investigational Plan (PIP) included in the EU Paediatric Regulation. Thus, G2B expects also to benefit from: (i) reduction of registration taxes; (ii) tax deductions; (iii) access to financial support; (iv) assistance in the drafting of clinical trial protocols; (v) ease of access to procedures to accelerate marketing in Europe; (vi) right to marketing exclusivity for 10 years in Europe; and (vii) 6-month extension patent protection initiative of medicines for children. The Health Economics & Market Access Outcomes Strategy that G2B will also perform will include a willingness-to-pay and product-market fit analysis, between others. The final report will help to estimate the economic value of the company considering relevant alternatives for both the healthcare system and pharmaceutical industry. The R&D strategy of G2B is focused on the therapeutic validation of its Platform to demonstrate its safety and efficacy. With SME designation and PIP, G2B will be able to successfully initiate first in human clinical trials in pediatric population.

Keywords: peptide shuttle,central nervous system,blood brain barrier,diffuse intrinsic pontine glioma,glioblastoma,small medium size enterprises,orphan drug designation,market access outcomes strategy
High-resolution cryo-EM structures of the human and yeast Sin3 histone deacetylase complexes (HDACbyCRYOEM)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Belgium
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-10-01
End date: 2024-09-30
Duration (months): 24.0
Total project cost (EUR): 191760.0
EU funding (EUR): 191760.0
Participants: 1
Project status: CLOSED

Histone deacetylase (HDAC) complexes are the main transcriptional repression machineries in eukaryotes. Disruption of their functions can lead to various diseases such as cancers, inflammatory diseases, and neurological disorders. HDAC complexes are composed of multiple subunits that assemble around HDAC enzymes, which have been the most exploited targets for developing small molecule therapeutics. To expand the diversity of targets and inhibitors available to study HDAC complex biology and fight HDAC-related diseases, the applicant developed phenotypic screens focused on the Sin3 HDAC complex in human and yeast during his PhD training. He also used proteomics approaches to study the global cellular effects of new compounds and predict their targets. However, the absence of high-resolution 3D structures for the Sin3 HDAC complex has hampered the precise understanding and validation of how drugs bind to specific subunits and perturb the overall architecture of the complex to reprogram its biological functions. Here, we are combining the expertise of the applicant in HDAC complex biology and druggability, to that of his host laboratory in cryo-electron microscopy (cryo-EM) to solve the 3D structures of the human and yeast Sin3 HDAC complex at near atomic resolution. This complex is highly conserved between species and is formed by a dozen proteins, making it an ideal candidate for single-particle cryo-EM. The applicant has already acquired promising preliminary data, including partial purifications of both human and yeast Sin3 HDAC complexes. The pioneer structures that will emerge from this work will have a high impact in the fields of transcriptomics and epigenetics since they will improve our understanding of HDAC complex arrangements, while helping validating long-standing hypotheses on transcriptional repression mechanisms. The proposed 3D models will also serve as starting points for further systematic structure-based design of new HDAC complex inhibitors.
Fostering capacity building for civic resilience and participation: Dialogic communication ethics and accountability (DIACOMET)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Culture, creativity and inclusive society
Theme: Culture, creativity and inclusive society
Destination: Innovative Research on Democracy and Governance
Action type: Research and Innovation actions
Countries involved: Lithuania,Estonia,Finland,Austria,Slovenia,Netherlands,Hungary,Switzerland
Call: Media for democracy – democratic media (HORIZON-CL2-2022-DEMOCRACY-01, 2022)
Start date: 2023-06-01
End date: 2026-05-31
Duration (months): 36.0
Total project cost (EUR): 2998012.5
EU funding (EUR): 2998012.5
Participants: 10
Project status: SIGNED

Digital communication enormously expands the number of ways people can interact and engage, but also challenges European societies by spread of conflict instigation, hate speech, and increasing amount of disinformation. The many initiators of destructive communication acts are various actors with diverse interests, who are not bound by either professional or ethical rules or obligations to distribute truthful information or stand for its reliability. The existing framework of public communication does not empower citizens to influence the ways the media institutions and actors operate in European democracies. DIACOMET contributes to the advancement of ethical and accountable communication by fostering capacity building for civic resilience against information distortions and promoting civic accountability. Therefore, DIACOMET aims to generate a concept of dialogic communication ethics (DCE), which would provide a framework for an inclusive model of accountability mechanisms that combine media accountability (the level of organisations) with civic accountability (the level of citizens) and is guided by a Civic Code of Good Communication Conduct (CGC) (a new type of code of communication ethics). The DIACOMET proposal explicitly addresses the aims of the Horizon Europe Culture, creativity and inclusive society Work Programme, the Topic, the Call and the European Democracy Action Plan through: 1. Analysis of the role of dialogic communication in existing ethics codes and guidelines and formulation of the CGC. 2. A novel concept of inclusive civic accountability bodies and a tested accountability mechanism. 3. An interactive ‘dilemma game’ and a forum for learning and discussion. DIACOMET proposes to establish a European network of civic accountability bodies for supporting individuals, groups and organizations to implement the CGC, and to assist in managing ethical issues emerging in public communication.

Keywords: dialogic communication ethics,civic accountability mechanisms,civic resilience,participation,democratic governance,civic code of good communication conduct
Exudation Agriculture: Highly Efficient and Continued Production of Carminic Acid Pigment for the Natural Colorants Industry (LemnaTap)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Israel
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2025-POC, 2025)
Start date: 2025-08-01
End date: 2027-01-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: SIGNED

Natural pigments are gaining importance in the EU as safer and more sustainable alternatives to synthetic colorants, but their use also presents challenges which have been hindering their wide adoption in the colorants market, particularly in terms of scalability, cost, and ethical sourcing. Carminic acid is widely used as a natural alternative and exemplifies these production challenges: it requires a labour-intensive extraction process, has negative ethical and environmental impacts for insect cultivation and exploitation, and its production is unpredictable due to external factors like weather fluctuations. Our PoC project introduces a groundbreaking technology for the sustainable production of target metabolites like Carminic acid. We aim to demonstrate the feasibility of using our innovative technology to produce cheaper and more sustainable natural colorants and to develop a comprehensive Business Plan to ensure the technology's market readiness and sustainability. Furthermore, we will conduct thorough market analysis and industry discussions to test our business case with relevant stakeholders, while also identifying potential funding sources to support future commercialization efforts.
Unraveling Parkinson´s disease diagnostic (UNMASK)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Portugal,Italy
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2023-POC, 2023)
Start date: 2024-07-01
End date: 2026-06-30
Duration (months): 24.0
Total project cost (EUR): 164820.0
EU funding (EUR): 150000.0
Participants: 2
Project status: SIGNED

Parkinson´s disease (PD) is a progressive, chronic, and debilitating neurodegenerative disease for which there is no cure and no diagnostic test available. About 10 million people live with PD worldwide (1.2 million in Europe), and this number is expected to double by 2030 due to the aging population. PD has a high social and economic burden, and there is the need to improve PD timely detection and diagnosis, especially in young people. UNMASK aims to validate the technological and business feasibility of the olfaction-inspired technology developed in the ERC Starting Grant SCENT by establishing the proof-of-concept for the non-invasive and fast PD diagnostics. To accomplish this, we will approach the project from both Technical and Business perspectives, with a perfect synergy between the research and business teams, and a close contact with clinical collaborators and stakeholders.
MATERNAL AND INFANT SAFETY AND IMMUNOGENICITY IN A PHASE 3, OPEN-LABEL, RANDOMISED, VACCINE TRIAL OF A TWO-DOSE MPOX VACCINE (PregInPoxVac)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Public-private partnerships
Destination: Global Health EDCTP3
Action type: Research and Innovation actions
Partnership: EDCTP3 (JU-JTI)
Countries involved: Belgium,Congo, The Democratic Republic of the,Italy,Kenya
Call: Mobilisation of Emergency funding for Mpox outbreak research response (HORIZON-JU-GH-EDCTP3-2024-Mpox, 2024)
Start date: 2024-08-01
End date: 2027-07-31
Duration (months): 36.0
Total project cost (EUR): 1599327.5
EU funding (EUR): 1599327.5
Participants: 4
Project status: SIGNED

Mpox can cause severe complications in vulnerable groups such as pregnant women and children, necessitating targeted public health interventions and vaccine trials in these populations. Limited data suggest the MVA-BN vaccine is safe for pregnant women and likely poses no risk to breastfed infants, but comprehensive human data are lacking. Trials in endemic areas are crucial for evaluating the vaccine's safety and efficacy in real-world settings. Vaccine hesitancy, exacerbated by misinformation and distrust in healthcare systems, poses a significant challenge, especially in the Democratic Republic of the Congo. Pregnant women are particularly affected by concerns about vaccine safety, which influences their willingness to vaccinate. Addressing these concerns through targeted communication and community engagement is vital. A proposed phase 3, randomized trial will assess the safety and immunogenicity of the MVA-BN vaccine in healthy pregnant and postpartum women and in infants/children (6-24 months old). Additionally, a qualitative study on vaccine hesitancy will inform the trial design and implementation, aiming to enhance vaccination uptake in these high-risk groups.

Keywords: pregnancy,infants,children,vaccination,pre exposure,post exposure,phase 2,mpox
PERSONALIZED REHABILITATION VIA NOVEL AI PATIENT STRATIFICATION STRATEGIES (PREPARE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
Action type: Research and Innovation actions
Countries involved: Greece,Italy,Netherlands,Slovenia,Cyprus,Ireland,Sweden,Switzerland,United Kingdom
Call: Computational models for new patient stratification strategies (HORIZON-HLTH-2022-TOOL-12-two-stage, 2022)
Start date: 2023-06-01
End date: 2027-05-31
Duration (months): 48.0
Total project cost (EUR): 5774112.5
EU funding (EUR): 5774112.5
Participants: 20
Project status: SIGNED

PREPARE aims at advancing rehabilitation care for patients with chronic non-communicable diseases. As rehabilitation is a complex, multifaceted, and highly personal process, we currently lack reliable patient stratification and outcome prediction tools. While big data approaches provide a path forward, existing data sets pose numerous challenges. These challenges can be overcome by combining advances in clinical research, socio-behavioral and public health research, data science, and advanced statistical and AI learning methods. We will apply machine learning techniques on our large-scale patient data sets including key sociodemographic, living conditions, and behavioral information to stratify patients based on expected outcomes. A subsequent analysis will consider all potential predictors for rehabilitation outcome. Baseline strata and modifiers will be used to develop a comprehensive model of each clinical situation to increase management quality, improve outcomes, and reduce costs. As proof of principle we will develop a platform for sharing model results, exploiting the open-science EHDEN platform, and showcase the novel approach through pilot cases of nine pathologies which constitute the most dominant causes for rehabilitation worldwide: hand disorders, hip and knee prosthesis, intermittent claudication, lower limb loss, Parkinson’s disease/Parkinsonisms, scoliosis, spine disorders, temporo-mandibular articulation, and hypertension. We will also develop a certification roadmap. PREPARE will result in innovative, robust, personalized, and validated data-driven computational prediction and stratification tools to support healthcare professionals and patients in selecting the optimal therapy strategy.

Keywords: personalized rehabilitation,hand,limb and spine disorders,stroke,intermittent claudication
Enhancing Protections through the Collective Auditing of Algorithmic Personalization (personAlg)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Computer Science and Informatics
Panel description: Informatics and information systems, computer science, scientific computing, intelligent systems
Countries involved: Israel
Call: ERC CONSOLIDATOR GRANTS (ERC-2023-COG, 2023)
Start date: 2024-09-01
End date: 2029-08-31
Duration (months): 60.0
Total project cost (EUR): 1741309.0
EU funding (EUR): 1741309.0
Participants: 1
Project status: SIGNED

The structure of the current data ecosystem carries grave threats to individuals' privacy and autonomy, facilitates discrimination, promotes social fragmentation, and threatens our ability to govern ourselves. Many of these concerns stem specifically from algorithmic personalization---the practice of providing individuals with personalized opportunities, information, or experiences, on the basis of their personal data and on patterns learned from others' data. Despite the urgency of the algorithmic personalization problem, the mathematical toolkit for studying and auditing for problematic algorithmic personalization remains extremely limited---particularly if we wish to do so in a manner that provides formal privacy guarantees. The goal of this proposal is to tackle this important problem head-on by establishing the mathematical foundations needed to study algorithmic personalization and to collectively audit personalization systems while guaranteeing privacy to participants. Such tools could transform our collective ability to make the best possible use of our data while ensuring autonomy, privacy, and overall positive social impact. My vision focuses on three core objectives: (1) building new mathematical concepts and definitions allowing us to articulate, prioritize, and study personalization-based problems, (2) addressing the key algorithmic challenges of privacy-preserving auditing of personalization systems, and (3) integrating deep understanding of the broader legal and ethical context into our approach. For each of these components, the proposal maps out a concrete research strategy, including preliminary steps that indicate the feasibility of this groundbreaking project.

Keywords: algorithmic fairness,differential privacy,algorithms and policy